Sn-117m-DOTA-annexin V

Drug Profile

Sn-117m-DOTA-annexin V

Alternative Names: [Tin-117m]-DOTA-annexin V; Tin-Annexin

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator Clear Vascular
  • Class Anti-inflammatories; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis

Most Recent Events

  • 09 Feb 2016 Phase-II clinical trials in Atherosclerosis in Chile (IV) prior to February 2016
  • 09 Feb 2016 Phase-II clinical trials in Atherosclerosis (Diagnosis) in Chile (IV) prior to February 2016
  • 19 Sep 2013 Phase-I clinical trials in Atherosclerosis (Diagnosis) in Chile (IV) prior to September 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top